The Indian Competition Authority orders pharma companies and trade association to cease and desist from indulging in anti-competitive business practices (Alkem Laboratories / McLeod’s Pharmaceuticals / Bengal Chemists and Druggists Association)

KEY POINTS The CCI recognised that there is rarely any direct evidence of action in cases involving concerted action. It is normal for agreements relating to such activities to be entered into in a clandestine manner. In such situations, the evidence is limited, fragmentary and sparse. Hence, it is necessary to reconstruct certain details by deduction. In most cases, the existence of an anti-competitive practice or agreement has to be inferred from a number of coincidences and indicia which, taken together, may, in the absence of any other plausible explanation, constitute evidence of the existence of an

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteurs

Citation

Charanya Lakshmikumaran, Neelambera Sandeepan, Badri Narayanan, Aditya Bhattacharya, The Indian Competition Authority orders pharma companies and trade association to cease and desist from indulging in anti-competitive business practices (Alkem Laboratories / McLeod’s Pharmaceuticals / Bengal Chemists and Druggists Association), 12 mars 2020, e-Competitions March 2020, Art. N° 107866

Visites 33

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues